RxDoctor Payments Data

Caroline Goldin, MD

Neurology · New Orleans, LANPI 1891189296

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (46.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Novocure Inc. at 48.6% of the total. Among neurology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,312in general payments, 2019–2025

Across 42 payments — averaging $864.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novocure Inc.$18K
  • Medtronic$9K
  • Boston Scientific$8K
  • AstraZeneca$2K
  • Day One Biopharmaceuticals$15
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Jazz Pharmaceuticals Inc.$2K

What the payments were for

  • Consulting fees$14,80041%
  • Speaking & faculty fees$1,5004%
  • Grants$16,87546%
  • Travel & lodging$1,1403%
  • Food & beverage$1,9986%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novocure Inc.36$17,639
Medtronic(2 entities)2$9,483
Boston Scientific2$7,625
AstraZeneca1$1,550
Day One Biopharmaceuticals1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,312 in reported general payments places this provider in the 90th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,786
Medicare patients
83
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Everolimus16$26,138
GleostineLomustine11$11,280
EliquisApixaban16$9,045
Lacosamide15$2,870
Levetiracetam66$2,248
Primidone18$1,157
Dexamethasone33$555
RivastigmineRivastigmine Tartrate16$529
Sertraline Hcl11$381
Oxcarbazepine11$360
Gabapentin31$271
Baclofen13$252
Propranolol Hcl ErPropranolol Hcl12$185
Ondansetron Hcl31$158
Clonazepam15$155

Paid to pharmacies, not to this prescriber.

Other neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →